Werfen Life Divests to Focus on the Hemostasis Market

Werfen Life Divests to Focus on the Hemostasis Market

The growing prevalence of autoimmune and blood disorders has put a spotlight on the science of hemostasis, the process of stopping bleeding and keeping blood within the damaged blood vessel. The coagulation/hemostasis analyzer market is expected to reach $4.84 billion by 2021, according to a report from MarketsandMarkets. Among the products, clinical laboratory analyzers are expected to account for the largest share of the market. Some big name players are already strengthening their hemostasis portfolios. In December 2015, Mallinckrodt plc (NYSE: MNK) purchased a global portfolio of three hemostasis products from The Medicines Company (NASDAQ: MDCO) for an upfront payment of $175... Read More »